Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce the appointment of Dr. Maziar Assadi Gehr in the role of Medical Director.  Dr. Gehr will spearhead the development of our pivotal trial, drawing upon his extensive expertise in various facets of the drug development process, including biomarker research, clinical development, and medical affairs.  The entire Immunophotonics team is excited to welcome him aboard.  His presence will enhance our clinical development efforts and further contribute to our continuous success.